pharmaceuticals

Three ways technology is improving pharmacyTechnology advances in pharmacy include innovations that improve medication safety, efficiency, and patient compliance.
Incremental clinical advances for Duchenne Muscular DystrophyJust last year, the FDA approved Exondys 51 (eteplirsen) for DMD, over the recommendations of FDA scientists and an external scientific advisory committee. Read more.
Will Trump follow through with an ACA repeal?In this commentary, Gerard J. Wedig of Simon Business School discusses the many possible implications of a Trump presidency.
Four things health execs should know about the oncology pipeline
Four things health execs should know about the oncology pipelineHere’s how you can recognize changes in the oncology pipeline and maximize value related to cancer care.
Drug pipeline developments: Alopecia areata and atopic dermatitisPromising treatments are coming for alopecia areata and atopic dermatitis, but they will come at a high cost.
Managed care pharmacy survey findings 2016To identify the top managed care pharmacy challenges and what your peers are doing about them, Managed Healthcare Executive, in partnership with Access Market Intelligence and the National Institute of Collaborative Healthcare, conducted its first-ever pharmacy survey during the second quarter of 2016.
Can costs be contained?There’s a lot of blame to go around when it comes to why drug costs are rising in dermatology. We’ll let the research do the finger pointing.
Industry payments (even free lunches) influence docs’ prescribingResearchers examining Medicare prescribing patterns of oral anticoagulants and non-insulin diabetes drugs have found that pharmaceutical marketing to physicians involving payments was associated with physicians being more likely to prescribe those marketed drugs.
Top 4 pharmacy trends healthcare executives should watch
Top 4 pharmacy trends healthcare executives should watchManaged Healthcare Executive conducted its first-ever managed care pharmacy survey during the second quarter of 2016 in partnership with Access Market Intelligence. Here’s a look at some of the key findings, with experts weighing in on the results.
Asthma drug pipeline: Prevalence, costs to increase
Asthma drug pipeline: Prevalence, costs to increaseAs asthma prevalence continues to rise in the adult and pediatric populations, U.S. healthcare spending on medications, especially branded inhalers, is expected to increase.